Core Viewpoint - The company, Taiankang (301263.SZ), has received approval from the National Medical Products Administration for a clinical trial of its drug CKBA for the treatment of rosacea, marking a significant advancement in its product pipeline [1]. Group 1: Clinical Trial Approval - Taiankang's subsidiary, Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd., has been granted a Clinical Trial Approval Notice for CKBA, allowing it to conduct a seamless adaptive clinical trial for the II/III phase [1]. - The approval is specifically for the indication of rosacea, which indicates the company's focus on dermatological conditions [1]. Group 2: Drug Characteristics - CKBA is a small molecule drug derived from the active ingredient of traditional Chinese medicine, frankincense, optimized through structural modification [1]. - The drug possesses a novel structure, independent intellectual property rights, a clear mechanism of action, and good safety profile [1]. Group 3: Mechanism of Action - CKBA directly targets and inhibits key enzymes ACC1 and ACC2 involved in the synthesis and metabolism of long-chain fatty acids [1]. - It regulates the differentiation of naive CD4+ T cells into Th17 cells, significantly downregulating IL-17A expression and reducing inflammatory cell infiltration [1]. - This mechanism aims to improve the typical inflammatory response and erythema associated with rosacea [1].
泰恩康(301263.SZ)：控股子公司CKBA乳膏玫瑰痤疮适应症获得药物临床试验批准通知书